CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 21 enrolled
Drug / intervention
fesoterodinedrug
Likely dose
fesoterodine 4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01367886
NCT01367886N/ACompleted
CompareCT.gov

Comparative Urine Proteomic Studies of Overactive Bladder in Humans

Washington University School of Medicine·interventional·Posted Jun 7, 2011·Updated Feb 27, 2015

In Brief

A clinical study evaluating fesoterodine for Overactive Bladder. Completed, enrolled 21 participants across 1 site.

Detailed Summary

This study is being done to evaluate the use of a new technology (urine proteomics) - the study of proteins in the urine to identify urine markers of overactive bladder (OAB) from a simple voided urine specimen.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOveractive Bladder
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJun 7, 2011
Enrollment StartAug 1, 2010
Primary CompletionSep 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 15.1 years ago

Interventions

fesoterodinedrug

Fesoterodine 4 mg. tablet by mouth daily for six weeks